Recro Pharma Inc. (NASDAQ:REPH) shares dropped 5.6% during mid-day trading on Tuesday . The company traded as low as $8.00 and last traded at $8.30, with a volume of 122,096 shares trading hands. The stock had previously closed at $8.79.

REPH has been the topic of a number of research reports. HC Wainwright reiterated a “buy” rating on shares of Recro Pharma in a research report on Monday, July 18th. Zacks Investment Research downgraded shares of Recro Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 18th. Finally, Brean Capital reiterated a “buy” rating and set a $28.00 target price on shares of Recro Pharma in a research report on Thursday, August 11th.

The firm’s market cap is $84.86 million. The firm has a 50-day moving average of $8.56 and a 200-day moving average of $7.40.

Recro Pharma (NASDAQ:REPH) last posted its quarterly earnings results on Thursday, August 11th. The specialty pharmaceutical company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.78) by $0.05. The business had revenue of $17.30 million for the quarter, compared to analysts’ expectations of $18.70 million. Analysts forecast that Recro Pharma Inc. will post ($1.83) EPS for the current year.

In related news, Director Winston J. Churchill sold 58,331 shares of Recro Pharma stock in a transaction on Friday, May 20th. The shares were sold at an average price of $7.91, for a total value of $461,398.21. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Scp Vitalife Partners (Israel) sold 6,260 shares of Recro Pharma stock in a transaction on Friday, May 20th. The shares were sold at an average price of $6.46, for a total transaction of $40,439.60. Following the completion of the sale, the insider now owns 783,642 shares in the company, valued at approximately $5,062,327.32. The disclosure for this sale can be found here.

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery. The Company’s lead product is an intranasal formulation of Dexmedetomidine (Dex). Its product candidates for pain indications include: Dex-IN, Dex-SL and Fadolmidine (Fado).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.